A Phase 1b/2 Study of OMP-59R5 (Tarextumab) in Combination With Nab-Paclitaxel and Gemcitabine in Subjects With Previously Untreated Stage IV Pancreatic Cancer

Clinical trial NCT01647828 · COMPLETED

Trial details

NCT number: NCT01647828
Sponsor: OncoMed Pharmaceuticals, Inc.
Status: COMPLETED
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Stage IV Pancreatic Cancer

Start date: 2012-10-01
Primary completion: 2016-04-01
Enrollment: 217

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.